IkeOluwa Lagunju1,2, Biobele J Brown1,2, Olugbemiro Sodeinde1,2. 1. Department of Paediatrics, College of Medicine, University of Ibadan, Ibadan, Nigeria. 2. Department of Paediatrics, University College Hospital, Ibadan, Nigeria.
Abstract
BACKGROUND: Sickle cell anaemia (SCA) is the leading genetic disorder in Nigeria. Elevated velocities ≥170 cm/sec occur in about a third of Nigerian children with SCA. Chronic blood transfusion for stroke prevention is faced with a myriad of challenges in our practice. OBJECTIVES: To evaluate the effectiveness of hydroxyurea (HU) in reducing flow velocities in a cohort of Nigerian children with SCA and elevated velocities treated with HU. METHODS: An observational study was carried out on a cohort of Nigerian children with SCA and elevated velocities identified on routine transcranial Doppler (TCD) screening. HU was recommended in those with TCD velocities ≥ 170cm/sec as stipulated in our hospital protocol. Outcomes were compared after ≥12 months of observation. RESULTS: Fifty children with elevated TCD velocities were studied; 31 consented to HU therapy and 19 declined. Children on HU showed a statistically significant decline in mean velocities from 199.7 [17.1] cm/sec to 165.8 [20.7] cm/sec (P < 0.001) with a significant increase in mean packed cell volume from 21.1 [3.4] to 25.0 [2.8]%. Children without treatment had a significant rise in mean velocities from 190.2 [10.8] cm/sec to 199.7 [14.9] cm/sec (P = 0.003). Children with conditional risk velocities on HU were less likely to convert to abnormal risk (P < 0.001). Two stroke events occurred, one in each group. No adverse effects of HU were recorded in the cohort. CONCLUSION: HU appears to significantly reduce TCD velocities in Nigerian children with SCA and elevated velocities ≥170 cm/sec with beneficial effect on the haematological profile. HU may provide an effective approach to primary stroke prevention, particularly in Africa.
BACKGROUND:Sickle cell anaemia (SCA) is the leading genetic disorder in Nigeria. Elevated velocities ≥170 cm/sec occur in about a third of Nigerian children with SCA. Chronic blood transfusion for stroke prevention is faced with a myriad of challenges in our practice. OBJECTIVES: To evaluate the effectiveness of hydroxyurea (HU) in reducing flow velocities in a cohort of Nigerian children with SCA and elevated velocities treated with HU. METHODS: An observational study was carried out on a cohort of Nigerian children with SCA and elevated velocities identified on routine transcranial Doppler (TCD) screening. HU was recommended in those with TCD velocities ≥ 170cm/sec as stipulated in our hospital protocol. Outcomes were compared after ≥12 months of observation. RESULTS: Fifty children with elevated TCD velocities were studied; 31 consented to HU therapy and 19 declined. Children on HU showed a statistically significant decline in mean velocities from 199.7 [17.1] cm/sec to 165.8 [20.7] cm/sec (P < 0.001) with a significant increase in mean packed cell volume from 21.1 [3.4] to 25.0 [2.8]%. Children without treatment had a significant rise in mean velocities from 190.2 [10.8] cm/sec to 199.7 [14.9] cm/sec (P = 0.003). Children with conditional risk velocities on HU were less likely to convert to abnormal risk (P < 0.001). Two stroke events occurred, one in each group. No adverse effects of HU were recorded in the cohort. CONCLUSION: HU appears to significantly reduce TCD velocities in Nigerian children with SCA and elevated velocities ≥170 cm/sec with beneficial effect on the haematological profile. HU may provide an effective approach to primary stroke prevention, particularly in Africa.
Authors: Léon Tshilolo; George Tomlinson; Thomas N Williams; Brígida Santos; Peter Olupot-Olupot; Adam Lane; Banu Aygun; Susan E Stuber; Teresa S Latham; Patrick T McGann; Russell E Ware Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245
Authors: Jane S Hankins; Mary Beth McCarville; Angela Rankine-Mullings; Marvin E Reid; Clarisse L C Lobo; Patricia G Moura; Susanna Ali; Deanne P Soares; Karen Aldred; Dennis W Jay; Banu Aygun; John Bennett; Guolian Kang; Jonathan C Goldsmith; Matthew P Smeltzer; James M Boyett; Russell E Ware Journal: Am J Hematol Date: 2015-11-17 Impact factor: 10.047
Authors: Bamidele O Tayo; Titilola S Akingbola; Santosh L Saraf; Binal N Shah; Chinedu A Ezekekwu; Omowunmi Sonubi; Lewis L Hsu; Richard S Cooper; Victor R Gordeuk Journal: Am J Hematol Date: 2018-05-14 Impact factor: 10.047
Authors: Melanie E Fields; Kristin P Guilliams; Dustin Ragan; Michael M Binkley; Amy Mirro; Slim Fellah; Monica L Hulbert; Morey Blinder; Cihat Eldeniz; Katie Vo; Joshua S Shimony; Yasheng Chen; Robert C McKinstry; Hongyu An; Jin-Moo Lee; Andria L Ford Journal: Blood Date: 2019-03-11 Impact factor: 22.113